Telmisartan and Hydrochlorothiazide Antihypertensive Treatment Study in High Sodium Intake Population
Primary Purpose
Hypertension
Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Telmisartan
Hydrochlorothiazide
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Telmisartan, Hydrochlorothiazide, Efficacy, hypertension, high sodium intake
Eligibility Criteria
Inclusion Criteria:
- Age≥18
- Essential hypertension: systolic blood pressure (SBP) is between 140mmHg-179mmHg and diastolic blood pressure (DBP)<110mmHg OR DBP is between 90mmHg-109mmHg and SBP<180mmHg.
- Hypertension patients diagnosed by spot urine test (urine sodium≥200mmol/24h).
- Subjects are not using antihypertensive medicines or medicines which affect the blood pressure within a week.
- Subjects volunteer to be brought in the research and have signed informed consent form, given that they have understood the research content.
Exclusion Criteria:
- Females who are already pregnant, in lactation and intend to be pregnant.
- Patients who have seriously allergic reaction or angioneurotic edema when taking ARB; Patients who have allergic history of thiazide diuretic (HCTZ) or sulfonamides.
- Patients who do not want to stop or have to take the medicines which are also antihypertensive or affect the blood pressure, other than which provided by the research.
- Stroke or CHD patients who are diagnosed within 6 months. CHD patients are identified by being diagnosed by coronary arteriography or coronary CT angiography, having received coronary stent or coronary artery bypass surgery, or being diagnosed with acute myocardial infarction. Stroke patients are identified by being diagnosed with cerebral thrombosis, cerebral embolism, cerebral hemorrhage, subarachnoid hemorrhage or transient ischemic attack.
- Patients who are clearly diagnosed with following diseases: Congenital disease, myocardiopathy, serious arrhythmia, pulmonary heart disease, various of cardiac failure.
- Patients who are clearly diagnosed with following symptoms or diseases: Proteinuria or heavy proteinuria, renal insufficiency or serious renal function damage, hepatic insufficiency or serious hepatic function damage; retinal exudates or hemorrhage, or papilledema.
- Patients who are clearly diagnosed with serious or deadly diseases in other systems.
- Patients who get dementia or other serious diseases cannot cooperate with researchers.
- Patients who drink 200g white spirits per day in past week.
- Patients who meet other situations which are considered to be inappropriate to be enrolled into the study by researchers.
Sites / Locations
- Chinese Traditional Medicine Hospital of Anguo
- Boye hospital
- Lixian chinese traditional medicine hospital
- Gaoyang hospital
- People's hospital in Rongcheng
- Mancheng Hospital
- Shunping Hospital
- People's hospital of Tangxian
- Wangdu hospital
- Gaobeidian hospital
- Central hospital in Baigou
- The second hospital of Lai Shui
- Wenan Hospital
- Dacheng chinese traditional medicine hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Telmisartan
Hydrochlorothiazide
Arm Description
capsule,40mg per day,2 months
tablet, 25mg per day, 2 months
Outcomes
Primary Outcome Measures
The difference between 2 groups of the decrease ranges of SBPs before and after the intervention of the subjects
We will measure the SBP for all the participants( around 1400) at baseline and 2\4\8 weeks after intervention with Omron electronic sphygmomanometer HBP - 1300. We will compare the differences between 2 groups at all 4 time points.
Secondary Outcome Measures
The between-group difference of the decrease ranges of DBPs before and after the intervention of the subjects
We will measure the DBP for all the participants( around 1400) at baseline and 2\4\8 weeks after intervention with Omron electronic sphygmomanometer HBP - 1300. We will compare the differences between 2 groups at all 4 time points.
Full Information
NCT ID
NCT02255253
First Posted
September 24, 2014
Last Updated
March 9, 2015
Sponsor
The George Institute for Global Health, China
Collaborators
Peking University People's Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02255253
Brief Title
Telmisartan and Hydrochlorothiazide Antihypertensive Treatment Study in High Sodium Intake Population
Official Title
Efficacy of Telmisartan 40mg and Hydrochlorothiazide 25mg Monotherapy in High Sodium Intake Patients With Mild to Moderate Hypertension: a Multicenter Randomized Double-blinded Parallel Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
October 2014 (undefined)
Primary Completion Date
February 2015 (Actual)
Study Completion Date
March 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The George Institute for Global Health, China
Collaborators
Peking University People's Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
In this research, the investigators aim to compare the antihypertensive efficacy and safety of monotherapy of routine dose angiotensin receptor antagonist telmisartan (ARB) and diuretic Hydrochlorothiazide (HCTZ) in high sodium intake patients with mild to moderate hypertension. The research will be conducted in the rural area in Hebei province, where people have a high sodium diet in their daily life. The 1200 eligible subjects will be drawn from 12 local county-level hospitals. Subjects will be randomly allocated in double-blind manner into ARB or HCTZ group to be administered telmisartan 40mg per day or hydrochlorothiazide 25mg per day respectively. After two-month treatment, the investigators will evaluate and compare the antihypertensive efficacy and safety between the two therapies.
The first objective of the research is to compare the antihypertensive efficacy of monotherapy of routine dose of angiotensin receptor antagonist telmisartan (ARB) and diuretic Hydrochlorothiazide (HCTZ) in high sodium intake patients with mild to moderate hypertension.The second objective is to compare the safety between the two therapies applied.
Null Hypothesis-H0: There will be no efficacy differences of lowering the systolic pressure between treating high sodium intake patients with mild to moderate hypertension with telmisartan and hydrochlorothiazide.Alternative Hypothesis-H1: There will be efficacy differences of lowering the systolic pressure between treating high sodium intake patients with mild to moderate hypertension with telmisartan and hydrochlorothiazide.
This research is a multicenter randomized double-blinded parallel controlled trial targeting on high sodium intake patients with mild to moderate hypertension in China. The eligible 1200 subjects will be randomly divided into ARB and HCTZ two groups, treated with monotherapy of telmisartan 40mg per day or hydrochlorothiazide 25mg per day respectively. Then, the compliance of the patients will be followed after a week. The investigators will evaluate the efficacy of blood pressure control and the safety of the medicines after one month and two months of the beginning of therapies. Figure 1 shows the research process.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Telmisartan, Hydrochlorothiazide, Efficacy, hypertension, high sodium intake
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
1410 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Telmisartan
Arm Type
Experimental
Arm Description
capsule,40mg per day,2 months
Arm Title
Hydrochlorothiazide
Arm Type
Experimental
Arm Description
tablet, 25mg per day, 2 months
Intervention Type
Drug
Intervention Name(s)
Telmisartan
Other Intervention Name(s)
China Resources Double-crane Pharmaceutical Co., Ltd
Intervention Description
capsule,40mg per day,2 months
Intervention Type
Drug
Intervention Name(s)
Hydrochlorothiazide
Other Intervention Name(s)
Tianjin LiSheng Pharmaceutical Co., Ltd
Intervention Description
tablet, 25mg per day, 2 months
Primary Outcome Measure Information:
Title
The difference between 2 groups of the decrease ranges of SBPs before and after the intervention of the subjects
Description
We will measure the SBP for all the participants( around 1400) at baseline and 2\4\8 weeks after intervention with Omron electronic sphygmomanometer HBP - 1300. We will compare the differences between 2 groups at all 4 time points.
Time Frame
2 months
Secondary Outcome Measure Information:
Title
The between-group difference of the decrease ranges of DBPs before and after the intervention of the subjects
Description
We will measure the DBP for all the participants( around 1400) at baseline and 2\4\8 weeks after intervention with Omron electronic sphygmomanometer HBP - 1300. We will compare the differences between 2 groups at all 4 time points.
Time Frame
2 months
Other Pre-specified Outcome Measures:
Title
The between-group difference of the blood pressure control rates before and after the intervention of the subjects
Description
The patients whose SBP is less than 140 (150 for the old) and DBP less than 90 are thought to be controlled.
Time Frame
2 months
Title
The between-group difference of the changing ranges of FBG testing results before and after the intervention of the subjects
Description
Blood samples will be collected at baseline and the end of 2-month intervention for FBG test.
Time Frame
2 months
Title
The between-group difference of the incidence rates of hypokalemia after the intervention of the subjects
Description
Blood samples will be collected at baseline and the end of 2-month intervention for test
Time Frame
2 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age≥18
Essential hypertension: systolic blood pressure (SBP) is between 140mmHg-179mmHg and diastolic blood pressure (DBP)<110mmHg OR DBP is between 90mmHg-109mmHg and SBP<180mmHg.
Hypertension patients diagnosed by spot urine test (urine sodium≥200mmol/24h).
Subjects are not using antihypertensive medicines or medicines which affect the blood pressure within a week.
Subjects volunteer to be brought in the research and have signed informed consent form, given that they have understood the research content.
Exclusion Criteria:
Females who are already pregnant, in lactation and intend to be pregnant.
Patients who have seriously allergic reaction or angioneurotic edema when taking ARB; Patients who have allergic history of thiazide diuretic (HCTZ) or sulfonamides.
Patients who do not want to stop or have to take the medicines which are also antihypertensive or affect the blood pressure, other than which provided by the research.
Stroke or CHD patients who are diagnosed within 6 months. CHD patients are identified by being diagnosed by coronary arteriography or coronary CT angiography, having received coronary stent or coronary artery bypass surgery, or being diagnosed with acute myocardial infarction. Stroke patients are identified by being diagnosed with cerebral thrombosis, cerebral embolism, cerebral hemorrhage, subarachnoid hemorrhage or transient ischemic attack.
Patients who are clearly diagnosed with following diseases: Congenital disease, myocardiopathy, serious arrhythmia, pulmonary heart disease, various of cardiac failure.
Patients who are clearly diagnosed with following symptoms or diseases: Proteinuria or heavy proteinuria, renal insufficiency or serious renal function damage, hepatic insufficiency or serious hepatic function damage; retinal exudates or hemorrhage, or papilledema.
Patients who are clearly diagnosed with serious or deadly diseases in other systems.
Patients who get dementia or other serious diseases cannot cooperate with researchers.
Patients who drink 200g white spirits per day in past week.
Patients who meet other situations which are considered to be inappropriate to be enrolled into the study by researchers.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zhang Pu Hong
Organizational Affiliation
The George Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chinese Traditional Medicine Hospital of Anguo
City
Baoding
State/Province
Hebei
ZIP/Postal Code
071200
Country
China
Facility Name
Boye hospital
City
Baoding
State/Province
Hebei
ZIP/Postal Code
071300
Country
China
Facility Name
Lixian chinese traditional medicine hospital
City
Baoding
State/Province
Hebei
ZIP/Postal Code
071400
Country
China
Facility Name
Gaoyang hospital
City
Baoding
State/Province
Hebei
ZIP/Postal Code
071500
Country
China
Facility Name
People's hospital in Rongcheng
City
Baoding
State/Province
Hebei
ZIP/Postal Code
071700
Country
China
Facility Name
Mancheng Hospital
City
Baoding
State/Province
Hebei
ZIP/Postal Code
072150
Country
China
Facility Name
Shunping Hospital
City
Baoding
State/Province
Hebei
ZIP/Postal Code
072250
Country
China
Facility Name
People's hospital of Tangxian
City
Baoding
State/Province
Hebei
ZIP/Postal Code
072350
Country
China
Facility Name
Wangdu hospital
City
Baoding
State/Province
Hebei
ZIP/Postal Code
072450
Country
China
Facility Name
Gaobeidian hospital
City
Baoding
State/Province
Hebei
ZIP/Postal Code
074000
Country
China
Facility Name
Central hospital in Baigou
City
Baoding
State/Province
Hebei
ZIP/Postal Code
074004
Country
China
Facility Name
The second hospital of Lai Shui
City
Baoding
State/Province
Hebei
ZIP/Postal Code
074100
Country
China
Facility Name
Wenan Hospital
City
Lanfang
State/Province
Hebei
ZIP/Postal Code
065800
Country
China
Facility Name
Dacheng chinese traditional medicine hospital
City
Langfang
State/Province
Hebei
ZIP/Postal Code
065900
Country
China
12. IPD Sharing Statement
Citations:
PubMed Identifier
28509725
Citation
Zhang P, Wang H, Sun L, Zhang J, Xi Y, Wu Y, Yan LL, Li X, Sun N. Telmisartan and hydrochlorothiazide antihypertensive treatment in high sodium intake population: a randomized double-blind trial. J Hypertens. 2017 Oct;35(10):2077-2085. doi: 10.1097/HJH.0000000000001407.
Results Reference
derived
Learn more about this trial
Telmisartan and Hydrochlorothiazide Antihypertensive Treatment Study in High Sodium Intake Population
We'll reach out to this number within 24 hrs